Thomas J. Schuetz
Known title: Chief Executive OfficerCIK: 0001591464
Thomas J. Schuetz's purchase track record
How the stock did after each of Thomas J. Schuetz's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
14
of 14 since May 10, 2022
Stock higher 6 months later
71%
3 months: 57%
Median 6-month return
+46.2%
3 months: +15.1%
Beat the S&P 500
71%
median +48.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/27/2025 | CMPX | $21K | +49.3% | +137.4% | +14.3% |
| 3/10/2023 | CMPX | $34K | -5.4% | -31.0% | +15.4% |
| 2/27/2023 | CMPX | $80K | -28.5% | -39.2% | +11.3% |
| 2/15/2023 | CMPX | $77K | -18.6% | -39.5% | +6.2% |
| 1/24/2023 | CMPX | $165K | -37.3% | -40.1% | +13.7% |
| 9/26/2022 | CMPX | $57K | +180.0% | +65.3% | +8.8% |
| 9/1/2022 | CMPX | $88K | +58.6% | +25.5% | +0.4% |
| 8/10/2022 | CMPX | $85K | +56.3% | +46.6% | -2.2% |
| 8/1/2022 | CMPX | $39K | +19.7% | +45.8% | -2.5% |
| 6/21/2022 | CMPX | $56K | -0.7% | +64.0% | +1.5% |
| 6/13/2022 | CMPX | $116K | +48.3% | +116.9% | +6.4% |
| 6/1/2022 | CMPX | $146K | -5.8% | +40.8% | -0.5% |
| 5/23/2022 | CMPX | $111K | +10.5% | +55.1% | -0.6% |
| 5/10/2022 | CMPX | $100K | +62.8% | +159.1% | -4.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CMPX | ▼ Sell | Tax Withholding | 36,687 | $239K | 2/8/2026 | View on chart |
| CMPX | ▼ Sell | Tax Withholding | 46,777 | $250K | 1/9/2026 | View on chart |
| CMPX | ▲ Buy | Grant | 250,000 | $1.3M | 1/2/2026 | View on chart |
| CMPX | ▼ Sell | Tax Withholding | 44,025 | $213K | 11/16/2025 | View on chart |
| CMPX | ▲ Buy | Open Market | 10,000 | $21K | 5/27/2025 | View on chart |
| CMPX | ▼ Sell | Tax Withholding | 41,687 | $146K | 2/8/2025 | View on chart |
| CMPX | ▼ Sell | Tax Withholding | 58,054 | $108K | 1/9/2025 | View on chart |
| CMPX | ▼ Sell | Tax Withholding | 44,782 | $65K | 2/8/2024 | View on chart |
| CMPX | ▲ Buy | Grant | 637,500 | $1.2M | 1/9/2024 | View on chart |
| CMPX | ▼ Sell | Tax Withholding | 44,025 | $66K | 11/17/2023 | View on chart |
| CMPX | ▲ Buy | Open Market | 10,000 | $34K | 3/10/2023 | View on chart |
| CMPX | ▲ Buy | Open Market | 20,000 | $80K | 2/27/2023 | View on chart |
| CMPX | ▲ Buy | Open Market | 20,000 | $77K | 2/15/2023 | View on chart |
| CMPX | ▲ Buy | Grant | 500,000 | $0 | 2/8/2023 | View on chart |
| CMPX | ▲ Buy | Open Market | 20,000 | $81K | 1/31/2023 | View on chart |
| CMPX | ▲ Buy | Open Market | 20,000 | $84K | 1/24/2023 | View on chart |
| CMPX | ▲ Buy | Open Market | 10,000 | $23K | 9/28/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 15,000 | $34K | 9/26/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 15,000 | $45K | 9/7/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 15,000 | $42K | 9/1/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 15,000 | $46K | 8/17/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 15,000 | $40K | 8/10/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 15,000 | $39K | 8/1/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 20,000 | $56K | 6/21/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 20,000 | $47K | 6/16/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 30,000 | $69K | 6/13/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 30,000 | $85K | 6/6/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 20,000 | $61K | 6/1/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 20,000 | $61K | 5/26/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 18,355 | $50K | 5/23/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 20,215 | $50K | 5/17/2022 | View on chart |
| CMPX | ▲ Buy | Open Market | 27,836 | $50K | 5/10/2022 | View on chart |
| CMPX | ▲ Buy | Grant | 600,000 | $0 | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Compass Therapeutics faces analyst downgrades after FDA setback
Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.
Compass Therapeutics faces analyst downgrades after FDA setback. Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.